Chi-Med, AstraZeneca's savolitinib helps some Tagrisso-resistant EGFR lung cancer patients - FiercePharma

Chi-Med, AstraZeneca's savolitinib helps some Tagrisso-resistant EGFR lung cancer patients  FiercePharma

AstraZeneca's Tagrisso has taken the EGFR lung cancer market by storm, but some patients develop resistance to the therapy. Enter Chi-Med and its MET ...



Comments

Popular posts from this blog

Lymph node metastasis in cancer progression: molecular mechanisms, clinical significance and therapeutic ...

Stage 4 Lung Cancer Life Expectancy

A Review of the Etiology and Epidemiology of Bladder Cancer: All ...